Clinical trials: Atopic Dermatitis (Eczema)
Atopic Dermatitis
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
The objective of the proposed study is to evaluate the tolerability and effectiveness of a 1% topical ointment of tofacitinib for the treatment of mild to moderate atopic dermatitis in adults.
- Trial name
- NCT05487963
- Testing
- Tofacitinib Citrate
- Where
- Georgia
- Volunteers
- 40 people
- Sponsor
- CAGE Bio Inc.
Atopic Dermatitis
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment.
- Trial name
- AD-Sys (NCT05098821)
- Testing
- not applicable, observational study
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis
Emollients in the Management of Atopic Dermatitis
The purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.
- Trial name
- NCT01779258
- Testing
- glycerol, paraffin (liquid and white soft), Atopiclair®, Locatop@
- Where
- 15 sites in Estonia, France and 3 more
- Volunteers
- 347 people
- Sponsor
- Pierre Fabre Medicament
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer
Moderate to Severe Atopic Dermatitis
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD…
- Trial name
- CANDID (NCT06099704)
- Where
- 30 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that RHT-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 1 to 12 years, as compared to placebo.
- Trial name
- NCT03907228
- Testing
- RHT-3201
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Atopic Dermatitis (AD), Atopic Eczema
Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema
This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema.
- Trial name
- CRISA-AD (NCT07438509)
- Testing
- Crisaborole 2% Cream
- Volunteers
- 270 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Atopic Dermatitis
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
This study is not being conducted in the United States of America (USA). Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching).
- Trial name
- NCT00130364
- Testing
- Pimecrolimus
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Atopic Dermatitis
Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis
- Trial name
- NCT04725136
- Testing
- FURESTEM-AD inj
- Where
- 2 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis, Pruritus
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis.
- Trial name
- NCT04490109
- Testing
- B244, Vehicle
- Where
- 56 sites in United States
- Volunteers
- 547 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients.
The purpose of the study is to explore the effect of nature-based exposure on immunological biomarkers and the condition and symptoms of atopic skin.
- Trial name
- NCT06129136
- Testing
- Nature-based exposure by biodiversity component in lotion.
- Where
- Finland
- Volunteers
- 142 people
- Sponsor
- Uute Scientific Oy
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Skin Condition
Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)
This is a single-centre, prospective, randomized, open-label, controlled trial of 200 infants 42±7 days of age. Subjects will be randomized to one of two open label feeding intervention group: Intact Cow's Milk Protein Formula…
- Trial name
- NCT04763512
- Testing
- Intact Cow's Milk Protein Formula, Partially Hydrolysed Whey Formula
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
This study is not being conducted in the United States. To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".
- Trial name
- NCT00139581
- Testing
- Pimecrolimus
- Where
- Switzerland
- Sponsor
- Novartis
Dermatitis Atopic
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus.
- Trial name
- DIFFEREN-STAD (NCT04823130)
- Testing
- Dupilumab (SAR231893)
- Where
- 3 sites in United States, Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients
The systemic treatments for moderate to severe atopic dermatitis (AD) are limited to phototherapy and cyclosporine with the risks respectively of either carcinoma, or hypertension or nephropathy.
- Trial name
- METHODA (NCT00809172)
- Testing
- Ciclosporin, Methotrexate
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Atopic Dermatitis
Prednisolone vs. Ciclosporine in Severe Atopic Eczema
To investigate the comparative efficacy of Ciclosporine A and Prednisolone in adult patients with severe atopic dermatitis.
- Trial name
- PROVE (NCT00445081)
- Testing
- Prednisolone, Ciclosporine A
- Where
- 5 sites in Austria, Germany
- Volunteers
- 66 people
- Sponsor
- Technische Universität Dresden
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Atopic Dermatitis
Comprehending Atopic Risk Elements
Skin barrier impairment and familial atopy have been implicated as crucial risk factors for the development of atopic dermatitis (AD).
- Trial name
- CARE (NCT04325451)
- Where
- 2 sites in Israel
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- MYOR Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.